natgillin/translations-raw huggingface dataset:
I de undersøgelser, der så på Karveas virkning på blodtrykket, var Karvea mere effektivt end placebo til at nedsætte det diastoliske blodtryk, og virkningerne af Karvea svarede til virkningerne af de andre lægemidler mod forhøjet blodtryk.
In the blood pressure studies, Karvea was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Når Karvea blev anvendt sammen med hydrochlorothiazid, var virkningerne additive.
When used with hydrochlorothiazide, the effects of the two medicines were additive.
I den første undersøgelser vedrørende nyresygdom var Karvea mere effektivt end placebo til at reducere risikoen for at udvikle nyreskade som målt ved proteinudskillelse.
In the first kidney disease study, Karvea was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
I den anden undersøgelse vedrørende nyresygdom reducerede Karvea i løbet af undersøgelsen den relative risiko for en fordobling af blodkreatininniveauerne, behovet for en nyretransplantation eller dialyse, eller risikoen for dødsfald i løbet af undersøgelsen med 20%, sammenlignet med placebo.
In the second kidney disease study, Karvea reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant, or death during the study by 20% in comparison with placebo.
De mest almindelige bivirkninger ved Karvea (mellem 1 og 10 patienter ud af 100) er svimmelhed, kvalme eller opkastning, træthed, en forøgelse af kreatinkinaseindholdet i blodet (et enzym, der findes i musklerne).
The most common side effects with Karvea (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, fatigue (tiredness) and increases in blood creatine kinase (an enzyme found in muscles).
Karvea bør ikke anvendes til folk, som kan være overfølsomme (allergiske) over for irbesartan eller nogen af de øvrige indholdsstoffer.
Karvea should not be used in people who may be hypersensitive (allergic) to irbesartan or any of the other ingredients.
Hvorfor er Karvea blevet godkendt?
Why has Karvea been approved?
Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at fordelene ved Karvea er større end risiciene ved behandling af essentiel hypertension (forhøjet blodtryk) og nyresygdom hos patienter med hypertension og type 2- diabetes mellitus.
The Committee for Medicinal Products for Human Use (CHMP) decided that Karvea’ s benefits are greater than its risks for the treatment of essential hypertension and of renal disease in patients with hypertension and type 2 diabetes mellitus.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Karvea.
The Committee recommended that Karvea be given marketing authorisation.
Andre oplysninger om Karvea:
Other information about Karvea:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Karvea til Bristol- Myers Squibb Pharma EEIG den 27. august 1997.
The European Commission granted a marketing authorisation valid throughout the European Union for Karvea to Bristol-Myers Squibb Pharma EEIG on 27 August 1997.
Denne tilladelse blev fornyet den 27. august 2002 og den 27. august 2007.
The marketing authorisation was renewed on 27 August 2002 and on 27 August 2007.
Den fuldstændige EPAR for Karvea findes her.
The full EPAR for Karvea is available here.
EU- nummer EU/ 1/ 97/ 049/ 001 EU/ 1/ 97/ 049/ 002 EU/ 1/ 97/ 049/ 003 EU/ 1/ 97/ 049/ 004 EU/ 1/ 97/ 049/ 005 EU/ 1/ 97/ 049/ 006 EU/ 1/ 97/ 049/ 007 EU/ 1/ 97/ 049/ 008 EU/ 1/ 97/ 049/ 009 EU/ 1/ 97/ 049/ 010 EU/ 1/ 97/ 049/ 011 EU/ 1/ 97/ 049/ 012 EU/ 1/ 97/ 049/ 013 EU/ 1/ 97/ 049/ 014 EU/ 1/ 97/ 049/ 015 EU/ 1/ 97/ 049/ 016 EU/ 1/ 97/ 049/ 017 EU/ 1/ 97/ 049/ 018 EU/ 1/ 97/ 049/ 019 EU/ 1/ 97/ 049/ 020 EU/ 1/ 97/ 049/ 021 EU/ 1/ 97/ 049/ 022 EU/ 1/ 97/ 049/ 023 EU/ 1/ 97/ 049/ 024 EU/ 1/ 97/ 049/ 025 EU/ 1/ 97/ 049/ 026 EU/ 1/ 97/ 049/ 027 EU/ 1/ 97/ 049/ 028 EU/ 1/ 97/ 049/ 029 EU/ 1/ 97/ 049/ 030 EU/ 1/ 97/ 049/ 031 EU/ 1/ 97/ 049/ 032 EU/ 1/ 97/ 049/ 033 EU/ 1/ 97/ 049/ 034 EU/ 1/ 97/ 049/ 035 EU/ 1/ 97/ 049/ 036 EU/ 1/ 97/ 049/ 037 EU/ 1/ 97/ 049/ 038 EU/ 1/ 97/ 049/ 039
EU/ 1/ 97/ 049/ 001 EU/ 1/ 97/ 049/ 002 EU/ 1/ 97/ 049/ 003 EU/ 1/ 97/ 049/ 004 EU/ 1/ 97/ 049/ 005 EU/ 1/ 97/ 049/ 006 EU/ 1/ 97/ 049/ 007 EU/ 1/ 97/ 049/ 008 EU/ 1/ 97/ 049/ 009 EU/ 1/ 97/ 049/ 010 EU/ 1/ 97/ 049/ 011 EU/ 1/ 97/ 049/ 012 EU/ 1/ 97/ 049/ 013 EU/ 1/ 97/ 049/ 014 EU/ 1/ 97/ 049/ 015 EU/ 1/ 97/ 049/ 016 EU/ 1/ 97/ 049/ 017 EU/ 1/ 97/ 049/ 018 EU/ 1/ 97/ 049/ 019 EU/ 1/ 97/ 049/ 020 EU/ 1/ 97/ 049/ 021 EU/ 1/ 97/ 049/ 022 EU/ 1/ 97/ 049/ 023 EU/ 1/ 97/ 049/ 024 EU/ 1/ 97/ 049/ 025 EU/ 1/ 97/ 049/ 026 EU/ 1/ 97/ 049/ 027 EU/ 1/ 97/ 049/ 028 EU/ 1/ 97/ 049/ 029 EU/ 1/ 97/ 049/ 030 EU/ 1/ 97/ 049/ 031 EU/ 1/ 97/ 049/ 032
Særnavn Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea
Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea Karvea
Styrke 75 mg 75 mg 75 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 75 mg 150 mg 300 mg 75 mg 150 mg 300 mg 75 mg 75 mg 75 mg 75 mg 75 mg 150 mg 150 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 300 mg 300 mg 75 mg 150 mg 300 mg 75 mg 150 mg 300 mg 75 mg 150 mg 300 mg
75 mg 75 mg 75 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 75 mg 150 mg 300 mg 75 mg 150 mg 300 mg 75 mg 75 mg 75 mg 75 mg 75 mg 150 mg 150 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 300 mg 300 mg 75 mg 150 mg
Lægemiddelform Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet Filmovertrukket tablet
Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Emballage Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium)
Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu) Blister (PVC/ PVDC/ alu)
Paknings- størrelse 28 56 98 28 56 98 28 56 98 14 14 14 56 x 1 56 x 1 56 x 1 14 28 56 56 x 1 98 14 28 56 56 x 1 98 14 28 56 56 x 1 98 84 84 84 30 30 30 90 90 90
28 56 98 28 56 98 28 56 98 14 14 14 56 x 1 56 x 1 56 x 1 14 28 56 56 x 1 98 14 28 56 56 x 1 98 14 28 56 56 x 1 98 84 84
Ved en dosis på 150 mg, 1 gang dagligt, giver Karvea generelt en bedre 24 timers blodtrykskontrol end 75 mg.
Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Hos patienter som ikke er tilstrækkeligt kontrolleret på 150 mg, 1 gang dagligt, kan dosis af Karvea øges til 300 mg, eller andre antihypertensiva kan tilføjes.
In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other anti-hypertensive agents can be added.
4. 5).
In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).
5. 1).
The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see section 5.1).
Selvom dette ikke er dokumenteret for Karvea, kan der forventes en lignende effekt med angiotensin- II - receptorantagonister.
While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Der anbefales periodisk kontrol af serum- kalium - og serum- kreatinin, hvis Karvea anvendes til patienter med nedsat nyrefunktion.
Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Som med andre lægemidler, der påvirker renin- angiotensin- aldosteron systemet, kan der opstå hyperkaliæmi under behandling med Karvea, specielt i tilfælde af nyrefunktionsnedsættelse, klinisk proteinuri på grund af diabetisk nyresygdom, og/ eller hjertefejl.
Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/ or heart failure.
4. 5).
Lithium: the combination of lithium and Karvea is not recommended (see section 4.5).
På trods af dette er Karvea uden risiko blevet administreret sammen med andre antihypertensive lægemidler som beta- blokkere, langtidsvirkende calcium- antagonister samt diuretika af thiazidtypen.
Diuretics and other antihypertensive agents: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
4. 4).
Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).
4. 3) under amning.
Karvea is contraindicated (see section 4.3) during breast-feeding.
Karveas blodtrykssænkende effekt er tydelig i løbet af 1- 2 uger, og den maksimale effekt viser sig 4- 6 uger efter behandlingsstart.
The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy.
Hypertensive patienter med type 2 diabetisk nyresygdom IDNT studiet (Irbesartan Diabetic Nephropathy Trial) har vist, at irbesartan nedsætter progression af nyresygdom hos patienter med kronisk nyre insufficiens og klinisk proteinuri.
Hypertension and type 2 diabetes with renal disease The “ Irbesartan Diabetic Nephropathy Trial (IDNT) ” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria.
IDNT var et kontrolleret dobbelt- blindt morbiditets - og mortalitetsstudie, som sammenlignede Karvea, amlodipin og placebo.
IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo.
Hos 1715 hypertensive patienter med type 2 diabetes, proteinuri ≥ 900 mg/ dag og serum - kreatininværdier i intervallet 1, 0- 3, 0 mg/ dl, evalueredes langtidseffekterne (median 2, 6 år) ved Karvea med henblik på progression af nyresygdom og total mortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
Patienterne blev titreret fra 75 mg til en vedligeholdelsesdosis på 300 mg Karvea, fra 2, 5 mg til 10 mg amlodipin eller placebo i henhold til tolerance.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
I subgrupper bestående af kvinder og sorte patienter, henholdsvis 32% og 26% af den samlede forsøgspopulation, sås der ingen
In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
8 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Studiet undersøgte langtidsvirkningerne (2 år) af Karvea med henblik på progression til klinisk proteinuri (urinalbumin udskillelsesrate (UAER) > 300 mg/ dag, og en stigning i UAER på mindst 30% i forhold til baseline).
The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/ day, and an increase in UAER of at least 30% from baseline).
Regression til normo albuminuri (< 30 mg/ dag) forekom hyppigere i gruppen, der fik Karvea 300 mg (34%) end i placebogruppen (21%).
Regression to normoalbuminuria (< 30 mg/ day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
18 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
28 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Ved en dosis på 150 mg, 1 gang dagligt, giver Karvea generelt en bedre 24- timers blodtrykskontrol end 75 mg.
Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Hos patienter som ikke er tilstrækkeligt kontrolleret på 150 mg, 1 gang daglig, kan dosis af Karvea øges til 300 mg, eller andre antihypertensiva kan tilføjes.
In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other anti-hypertensive agents can be added.
Som med andre lægemidler, der påvirker renin- angiotensin- aldosteronsystemet, kan der opstå hyperkaliæmi under behandling med Karvea, specielt i tilfælde af nyrefunktionsnedsættelse, klinisk proteinuri på grund af diabetisk nyresygdom og/ eller hjertefejl.
Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/ or heart failure.
Det vides ikke om irbesartan udskilles i human modermælk.
Karvea is contraindicated (see section 4.3) during breast-feeding. It is not known whether irbesartan is excreted in human milk.
Hos 1. 715 hypertensive patienter med type2- diabetes, proteinuri ≥ 900 mg/ dag og serum - kreatininværdier i intervallet 1, 0- 3, 0 mg/ dl, evalueredes langtidseffekterne (median 2, 6 år) ved Karvea med henblik på progression af nyresygdom og totalmortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
Irbesartan reducerede signifikant den relative risiko i det kombinerede primære endepunkt med fordobling af serum - kreatinin, slutstadium af nyresygdom (ESRD) eller totalmortalitet.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all- cause mortality.
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
38 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
48 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
IRMA 2- studiet (Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
58 The study of the “ Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2) ” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
EU/ 1/ 97/ 049/ 010 14 tabletter EU/ 1/ 97/ 049/ 001 28 tabletter EU/ 1/ 97/ 049/ 002 56 tabletter EU/ 1/ 97/ 049/ 013 56 x 1 tabletter EU/ 1/ 97/ 049/ 003 98 tabletter
EU/ 1/ 97/ 049/ 010 14 tablets EU/ 1/ 97/ 049/ 001 28 tablets EU/ 1/ 97/ 049/ 002 56 tablets EU/ 1/ 97/ 049/ 013 56 x 1 tablets EU/ 1/ 97/ 049/ 003 98 tablets
EU/ 1/ 97/ 049/ 011 14 tabletter EU/ 1/ 97/ 049/ 004 28 tabletter EU/ 1/ 97/ 049/ 005 56 tabletter EU/ 1/ 97/ 049/ 014 56 x 1 tabletter EU/ 1/ 97/ 049/ 006 98 tabletter
EU/ 1/ 97/ 049/ 011 14 tablets EU/ 1/ 97/ 049/ 004 28 tablets EU/ 1/ 97/ 049/ 005 56 tablets EU/ 1/ 97/ 049/ 014 56 x 1 tablets EU/ 1/ 97/ 049/ 006 98 tablets
EU/ 1/ 97/ 049/ 012 14 tabletter EU/ 1/ 97/ 049/ 007 28 tabletter EU/ 1/ 97/ 049/ 008 56 tabletter EU/ 1/ 97/ 049/ 015 56 x 1 tabletter EU/ 1/ 97/ 049/ 009 98 tabletter
EU/ 1/ 97/ 049/ 012 14 tablets EU/ 1/ 97/ 049/ 007 28 tablets EU/ 1/ 97/ 049/ 008 56 tablets EU/ 1/ 97/ 049/ 015 56 x 1 tablets EU/ 1/ 97/ 049/ 009 98 tablets
EU/ 1/ 97/ 049/ 016 14 tabletter EU/ 1/ 97/ 049/ 017 28 tabletter EU/ 1/ 97/ 049/ 034 30 tabletter EU/ 1/ 97/ 049/ 018 56 tabletter EU/ 1/ 97/ 049/ 019 56 x 1 tabletter EU/ 1/ 97/ 049/ 031 84 tabletter EU/ 1/ 97/ 049/ 037 90 tabletter EU/ 1/ 97/ 049/ 020 98 tabletter
EU/ 1/ 97/ 049/ 016 14 tablets EU/ 1/ 97/ 049/ 017 28 tablets EU/ 1/ 97/ 049/ 034 30 tablets EU/ 1/ 97/ 049/ 018 56 tablets EU/ 1/ 97/ 049/ 019 56 x 1 tablets EU/ 1/ 97/ 049/ 031 84 tablets EU/ 1/ 97/ 049/ 037 90 tablets EU/ 1/ 97/ 049/ 020 98 tablets
EU/ 1/ 97/ 049/ 021 14 tabletter EU/ 1/ 97/ 049/ 022 28 tabletter EU/ 1/ 97/ 049/ 035 30 tabletter EU/ 1/ 97/ 049/ 023 56 tabletter EU/ 1/ 97/ 049/ 024 56 x 1 tabletter EU/ 1/ 97/ 049/ 032 84 tabletter EU/ 1/ 97/ 049/ 038 90 tabletter EU/ 1/ 97/ 049/ 025 98 tabletter
EU/ 1/ 97/ 049/ 021 14 tablets EU/ 1/ 97/ 049/ 022 28 tablets EU/ 1/ 97/ 049/ 035 30 tablets EU/ 1/ 97/ 049/ 023 56 tablets EU/ 1/ 97/ 049/ 024 56 x 1 tablets EU/ 1/ 97/ 049/ 032 84 tablets EU/ 1/ 97/ 049/ 038 90 tablets EU/ 1/ 97/ 049/ 025 98 tablets
EU/ 1/ 97/ 049/ 026 14 tabletter EU/ 1/ 97/ 049/ 027 28 tabletter EU/ 1/ 97/ 049/ 036 30 tabletter EU/ 1/ 97/ 049/ 028 56 tabletter EU/ 1/ 97/ 049/ 029 56 x 1 tabletter EU/ 1/ 97/ 049/ 033 84 tabletter EU/ 1/ 97/ 049/ 039 90 tabletter EU/ 1/ 97/ 049/ 030 98 tabletter
EU/ 1/ 97/ 049/ 026 14 tablets EU/ 1/ 97/ 049/ 027 28 tablets EU/ 1/ 97/ 049/ 036 30 tablets EU/ 1/ 97/ 049/ 028 56 tablets EU/ 1/ 97/ 049/ 029 56 x 1 tablets EU/ 1/ 97/ 049/ 033 84 tablets EU/ 1/ 97/ 049/ 039 90 tablets EU/ 1/ 97/ 049/ 030 98 tablets
INFORMATION TIL BRUGEREN Karvea 75 mg tabletter irbesartan
INFORMATION FOR THE USER Karvea 75 mg tablets irbesartan
Lægen har ordineret Karvea til dig personligt.
This medicine has been prescribed for you.
Lad derfor være med at give Karvea til andre.
Do not pass it on to others.
Karveas virkning og hvad du skal bruge det til 2.
What Karvea is and what it is used for 2.
Det skal du vide, før du begynder at bruge Karvea 3.
Before you take Karvea 3.
Sådan skal du bruge Karvea 4.
How to take Karvea 4.
Sådan opbevarer du Karvea 6.
How to store Karvea 6.
KARVEAS VIRKNING OG HVAD DU SKAL BRUGE DET TIL
WHAT KARVEA IS AND WHAT IT IS USED FOR
Karvea tilhører en medicingruppe, der kaldes angiotensin- II receptorantagonister.
Karvea belongs to a group of medicines known as angiotensin-II receptor antagonists.
Derved afslappes blodårerne, og blodtrykket falder.
Karvea prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Karvea mindsker faldende nyrefunktion hos patienter med forhøjet blodtryk og type 2 - diabetes.
Karvea slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.